Shattuck Labs Inc. (STTK)
NASDAQ: STTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
STTK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $454.22M
- EPS (TTM)
- -$0.47
- Dividend yield
- None
- 52-week range
- 1.93 – 8.33
- Day range
- 4.42 – 4.68
- Volume / Avg
- 1.03M / 1.20M
- Beta
- —
- Shares outstanding
- 101.84M
52-week range
STTK stock today
Shattuck Labs (STTK) closed at $4.46 on Nov 20, down 1.98% (-$0.09), versus the S&P 500's 3.70% decline. At this level, STTK sits in the middle of its 52-week range of $1.93 to $8.33: 46.5% below the high, set on Apr 20, 2026 and 131.1% above the low. STTK is up 22.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 119.7%.
Shattuck Labs has posted a net loss over the last twelve months (EPS of -$0.47), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Shattuck Labs
Company profileShattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Taylor H. Schreiber M.D., Ph.D.
- Headquarters
- Austin, TX
- Employees
- 40
- IPO year
- 2020
- Website
- shattucklabs.com
Financial highlights
Full financialsIn fiscal 2025, Shattuck Labs generated $1.0 million in revenue, down 82.5% from fiscal 2024, its first annual decline since 2022. Shattuck Labs reported a net loss of $48.8 million, compared with a loss of $75.4 million a year earlier. Operating margin was -5150.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.00M | $5.72M | $1.66M | $652.00K | $30.02M |
| Growth | -82.52% | +245.26% | +154.14% | -97.83% | +202.16% |
| Net income | $-48.81M | $-75.41M | $-87.30M | $-101.94M | $-44.97M |
| EPS (diluted) | $-0.70 | $-1.49 | $-2.05 | $-2.41 | $-1.07 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$15.40+245.29%
- Strong buy 3
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.14 vs $-0.10
- Surprise
- -40.00%
STTK news
All STTK newsShattuck Labs peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BLSMBlossomHill Therapeutics Inc. | 14.51 | +0.69% | $461.20M | vs STTK |
| RZLTRezolute Inc. | 3.92 | -6.67% | $465.58M | vs STTK |
| GYREGyre Therapeutics Inc. | 4.21 | -6.86% | $460.79M | vs STTK |
| MNPRMonopar Therapeutics Inc. | 69.00 | -1.84% | $467.60M | vs STTK |
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs STTK |
| EVOEvotec SE ADR | 1.32 | -8.97% | $469.11M | vs STTK |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs STTK |
| KMDAKamada Ltd. | 7.74 | -1.15% | $446.85M | vs STTK |
Indexes, lists and sector
Shattuck Labs stock FAQ
What is Shattuck Labs's stock price today?
STTK last traded at $4.46 as of Nov 20, 4:00 PM EST, down 1.98% on the day. Prices are delayed at least 15 minutes.
Who is Shattuck Labs's CEO?
Dr. Taylor H. Schreiber M.D., Ph.D. is the chief executive officer of Shattuck Labs Inc., which has about 40 employees.
What is the STTK 52-week high?
The 52-week high for STTK is $8.33 and the 52-week low is $1.93. The stock is currently 46.5% below its high.